<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1922">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366323</url>
  </required_header>
  <id_info>
    <org_study_id>AdiQure/COVID-19</org_study_id>
    <nct_id>NCT04366323</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19</brief_title>
  <official_title>Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Network for Design and Translation of Advanced Therapies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose
      Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS</intervention_name>
    <description>Two doses of 80 million adipose-tissue derived mesenchymal stem cells</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18

          2. Clinical diagnosis of Pneumonia, severe or critical, caused by COVID-19 infection

          3. Life expectancy &gt; 48 hours.

          4. Commitment to use a contraceptive method of proven efficacy in both men and women
             during the duration of the clinical trial.

        Exclusion Criteria:

          1. Coinfection with other viruses or bacteria (HIV, tuberculosis, influenza virus,
             adenovirus or other respiratory infections, active infection by HBV or C).

          2. History of multiple allergies, including allergy to Penicillin or other Blactams.

          3. Pregnant and lactating women.

          4. Patients with malignant tumors or hemopathies or any state of immunosuppression
             considered as severe.

          5. Patients with autoimmune diseases.

          6. Chronic heart failure with ejection fraction less than 30%.

          7. Any other condition for which, in the opinion of the main investigator, the subject is
             considered not to be in compliance with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Cardesa Gil</last_name>
    <phone>697 95 69 41</phone>
    <phone_ext>0034</phone_ext>
    <email>ana.cardesa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Estella García</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen de la Fuente Martos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Hidalgo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Rodríguez Baños</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Unversitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis López Cortés</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Loza Vázquez</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

